Related Experiment Video

Updated: Oct 15, 2026

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

Combination therapy for chronic Pseudomonas aeruginosa respiratory infection associated with biofilm formation

K Yanagihara1, K Tomono, T Sawai

  • 1The Second Department of Internal Medicine, Nagasaki University School of Medicine, 1-7-1 Sakamoto, Japan.

The Journal of Antimicrobial Chemotherapy
|July 7, 2000
PubMed

Insights

This study shows that a new mouse model effectively studies chronic Pseudomonas aeruginosa respiratory infections. Combination therapy with clarithromycin and levofloxacin significantly reduced bacteria in these biofilm-associated infections.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Chronic respiratory infections often involve bacterial biofilms, complicating treatment.
  • Previous in vivo studies on respiratory biofilms were lacking.
  • Pseudomonas aeruginosa is a common pathogen in chronic respiratory infections.

Purpose of the Study:

  • To evaluate the efficacy of combined clarithromycin and levofloxacin against chronic respiratory infection with Pseudomonas aeruginosa in a new murine model.
  • To investigate the in vivo formation and characteristics of Pseudomonas aeruginosa biofilms in a chronic respiratory infection model.

Main Methods:

  • Establishment of a murine model for chronic respiratory infection with Pseudomonas aeruginosa.
  • Scanning electron microscopy to visualize in vivo biofilm formation on implanted catheters.
  • Assessment of bacterial load in lung tissue following treatment with clarithromycin, levofloxacin, or combination therapy.

Main Results:

  • In vivo biofilm formation containing blood cells, fibrous structures, and bacteria was confirmed in the mouse bronchus.
  • Single-drug treatments (clarithromycin or levofloxacin) showed no significant reduction in viable bacteria.
  • Combination therapy with clarithromycin and levofloxacin resulted in a statistically significant decrease in bacterial numbers.

Conclusions:

  • The newly developed murine model is suitable for studying biofilm-associated chronic respiratory infections.
  • Combined clarithromycin and levofloxacin therapy is effective against Pseudomonas aeruginosa chronic respiratory infections, particularly those involving biofilms.

More Related Videos

Co-culture Models of Pseudomonas aeruginosa Biofilms Grown on Live Human Airway Cells11:21

Co-culture Models of Pseudomonas aeruginosa Biofilms Grown on Live Human Airway Cells

Published on: October 6, 2010

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung09:26

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

Published on: January 22, 2021

Related Concept Videos

Biofilms01:29

Biofilms

Biofilms are complex communities of microorganisms encased in a self-produced extracellular polysaccharide matrix attached to surfaces. These microbial consortia can include single or multiple species, providing enhanced survival benefits by forming organized, multilayered structures.The formation of biofilms occurs through four key stages: attachment, colonization, development, and dispersal.During attachment, free-swimming planktonic cells adhere to a surface, often facilitated by...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...